Back to News
Market Impact: 0.2
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C
Source: globenewswire.com
Healthcare & BiotechRegulation & Legislation
The NDA is supported by the Phase 3 TransportNPC™ study, data from earlier clinical studies, and an overall-survival analysis against external registry controls. The article fragment provides no efficacy figures, regulatory decision, or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Analysts react as Binance freezes assets after $6.3 billion security breach
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
- Spanish PM, facing reelection, says it’s ‘unacceptable’ to suffer two high-speed rail accidents in one year as at least 68 die in collision
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside